Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
SB 525334 Chemical Structure
|Product name: SB 525334|
|Cat. No.: HY-12043|
SB525334 is a potent and selective inhibitor of TGFβ receptor I (ALK5) with IC50 of 14.3 nM, is 4-fold less potent to ALK4 than ALK5 and inactive to ALK2, 3, and 6.
IC50 value: 14.3 nM
in vitro: SB 525334 shows no inhibition in the enzymes ALK2, 3, and 6, with IC50 values > 10 μM. SB 525334 blocks phosphorylation induced by TGF-β1 and nuclear translocation of Smad2/3 in renal proximal tubule cells. SB 525334 also inhibits the increased mRNA expression levels of plasminogen activator inhibitor-1 (PAI-1) and procollagen α1(I) induced by TGF-β1 in A498 renal epithelial carcinoma cells at 1 μM) . SB 525334 (1 μM) attenuates the heightened sensitivity to TGF-β1 exhibited by pulmonary artery smooth muscle cells (PASMCs) from patients with familial forms of idiopathic pulmonary arterial hypertension (PAH) .
in vivo: SB 525334 (10 mg/kg/day) decreases the renal mRNA levels of PAI-1, procollagen α1(I), and procollagen α1(III) in a nephritis-induced renal fibrosis rat model. Furthermore, PAN-induced proteinuria is significantly inhibited by SB 525334 (10 mg/kg/day) . SB 525334 may also be efficacious in mesenchymal tumors. SB 525334 (10 mg/kg/day) significantly decreases uterine mesenchymal tumor incidence, multiplicity, and size in Eker rats .
|M.Wt||343.42||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO ≥66mg/mL Water <1.2mg/mL Ethanol ≥66mg/mL
|1 mg||5 mg||10 mg|
|1 mM||2.9119 mL||14.5594 mL||29.1189 mL|
|5 mM||0.5824 mL||2.9119 mL||5.8238 mL|
|10 mM||0.2912 mL||1.4559 mL||2.9119 mL|
. Grygielko ET, et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther, 2005, 313(3), 943-951.
. Thomas M, et al. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol, 2009, 174(2), 380-389.
A 77-01 is a potent inhibitor of TGF-(beta) type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM.
A 83-01 is a selective inhibitor of TGF-(beta) type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50 values are 12, 45 and 7.5 nM respectively).
GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, also inhibits TGF-(beta) type II receptor and activin type II receptor activities, but does not inhibit BMP type II receptor.
ITD-1 is an inducer of TGF(beta) type II receptor degradation-1, is a potent and highly selective TGF(beta) pathway inhibitor (IC50 = 0.85 (mu)M).
LY364947 is a potent ATP-competitive inhibitor of TGF(beta)R-I with IC50 of 59 nM, exhibits 7-fold selectivity over TGF(beta)R-II.
LY2157299 is a potent TGF(beta) receptor I (T(beta)RI) inhibitor with IC50 of 56 nM.
RepSox(E-616452; SJN 2511) is a potent and selective inhibitor of the TGF(beta)R-1/ALK5 with IC50 of 23 nM and 4 nM for ATP binding to ALK5 and ALK5 autophosphorylation, respectively.
SD-208 is a potent, orally active ATP-competitive transforming growth factor-(beta) receptor 1 (TGF-(beta)RI) inhibitor (IC50= 49 nM); displays > 100-fold and > 17-fold selectivity over TGF-(beta)RII and other common kinases respectively.